Management of Recurrent Gastrointestinal Stromal Tumors

被引：15
作者：
Winer, Joshua H. [1 ,2 ]
Raut, Chandrajit P. [1 ,2 ,3 ]
机构：
[1] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF SURGICAL ONCOLOGY | 2011年 / 104卷 / 08期
关键词：
recurrent gastrointestinal stromal tumor; imatinib mesylate; sunitinib malate; surgery; neoadjuvant therapy; blood level testing; PHASE-II TRIAL; IMATINIB MESYLATE; SURGICAL RESECTION; RESIDUAL DISEASE; TYROSINE-KINASE; DOSE IMATINIB; GIST; THERAPY; SURGERY; KIT;
D O I：
10.1002/jso.21890
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recurrence after resection of primary gastrointestinal stromal tumor (GIST) is an unfortunately all-too-common phenomenon. The principal treatment for recurrent GIST is the first-line tyrosine kinase inhibitor (TKI) imatinib mesylate. Those who progress on, or are intolerant of imatinib, are treated with second-line TKI sunitinib malate. Cytoreductive surgery may be considered as an "adjuvant" therapy for patients with disease stabilized on imatinib, and, on an individual basis, sunitinib. J. Surg. Oncol. 2011;104:915-920. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码：915 / 920
页数：6
相关论文
共 44 条
  • [1] Surgical resection of gastrointestinal stromal tumors after treatment with imatinib
    Andtbacka, Robert H. I.
    Ng, Chaan S.
    Scaife, Courtney L.
    Cormier, Janice N.
    Hunt, Kelly K.
    Pisters, Peter W. T.
    Pollock, Raphael E.
    Benjamin, Robert S.
    Burgess, Michael A.
    Chen, Lei L.
    Trent, Jonathan
    Patel, Shreyaskumar R.
    Raymond, Kevin
    Feig, Barry W.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) : 14 - 24
  • [2] [Anonymous], 2010, IMITANIB MESYLATE DR
  • [3] Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
    Bauer, S
    Hartmann, JT
    de Wit, M
    Lang, H
    Grabellus, F
    Antoch, G
    Niebel, W
    Erhard, J
    Ebeling, P
    Zeth, M
    Taeger, G
    Seeber, S
    Flasshove, M
    Schütte, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) : 316 - 325
  • [4] Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
    Bauer, Sebastian
    Yu, Lynn K.
    Demetri, George D.
    Fletcher, Jonathan A.
    [J]. CANCER RESEARCH, 2006, 66 (18) : 9153 - 9161
  • [5] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Blanke, Charles D.
    Demetri, George D.
    von Mehren, Margaret
    Heinrich, Michael C.
    Eisenberg, Burton
    Fletcher, Jonathan A.
    Corless, Christopher L.
    Fletcher, Christopher D. M.
    Roberts, Peter J.
    Heinz, Daniela
    Wehre, Elisabeth
    Nikolova, Zariana
    Joensuu, Heikki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 620 - 625
  • [6] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [7] Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183
  • [8] Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Blay, Jean-Yves
    Adenis, Antoine
    Ray-Coquard, Isabelle
    Cassier, Philippe A.
    Le Cesne, Axel
    [J]. CURRENT OPINION IN ONCOLOGY, 2009, 21 (04) : 360 - 366
  • [9] Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era
    Bonvalot, S.
    Eldweny, H.
    Le Pechoux, C.
    Vanel, D.
    Terrier, P.
    Cavalcanti, A.
    Robert, C.
    Lassau, N.
    Le Cesne, A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (12) : 1596 - 1603
  • [10] Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy
    Braconi, C.
    Bracci, R.
    Cellerino, R.
    [J]. CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 359 - 366
12345